NEWS ARCHIVE

Read More

HALO® Deep Learning Technology Awarded for Automated Breast Cancer Metastasis Staging

Corrales, NM – April 24th 2017 – Indica Labs proudly announces its breakthrough HALO® Deep Learning technology excelled in the CameLyon17 diagnostic image analysis competition.  The international challenge engaged commercial and academic teams worldwide to develop deep-learning algorithms to analyze 500 whole-slide H&E lymph node images and calculate TNM staging of 100 breast cancer patients. The HALO Deep Learning solution was the highest ranking commercial solution and third overall among 32 accepted teams.

Indica’s CEO Steven Hashagen remarked “Our team is excited to learn the results of the competition. Cancer staging is critical for determining a patient’s prognosis and treatment, yet it is a very complex task for both machine and pathologist. Our HALO platform is at the forefront of cancer research, cancer diagnostics, and improvement of patient outcome, yet we’re just scratching the surface of what will be accomplished with the technology.

The HALO Deep Learning system combines multiple Neural Network technologies which are seamlessly integrated into HALO, the industry-leading digital pathology platform. Indica Labs has rolled out beta-evaluations of the technology to several pharmaceutical companies, academic medical centers, and the National Cancer Institute.  Official launch of the product is scheduled for July 2017.  Deployment options include both cloud-based and on-premise configurations.

Full results and details of the CameLyon17 competition can be found at https://camelyon17.grand-challenge.org/results/.  For more information, evaluation, and collaboration opportunities, please contact us at info@indicalab.com.

 

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-therapy, oncology, metabolism, toxicological pathology, neuroscience and more.

Indica Labs opens office in Tokyo to provide dedicated support to customers in Japan インディカ・ラボ社 国内拠点新設について

Tokyo, 9 January, 2017 – Indica Labs expanded its international presence again this month with the establishment of a new office in Tokyo, Japan and the recruitment of Hideya Makino to manage Japanese operations.  Mr. Makino has over 14 years of combined experience in the fields of microscopy, digital pathology and image analysis gained through his previous positions at Roche, Leica, Aperio, and Roper Technologies.

Indica Labs’ has been steadily growing its global business since 2012.  In addition to Tokyo, Indica Labs has representatives based in the United Kingdom and in the United States who provide dedicated support to customers in Europe and North America, respectively.

“Indica Labs is committed to providing superior service and support to all of our customers,” said Steven Hashagen, CEO of Indica Labs.  “In the last two years, the adoption of Indica Labs’ products in Asia, and especially in Japan, has risen dramatically.  Having local representatives [in Japan] who are dedicated to our products and who can respond to customers in a timely manner and in the local language is essential for providing top quality support to this growing customer base.  We are pleased to have Makino-san leading this effort on behalf of Indica Labs in Japan.”

Customers in Japan with sales and support inquires, can contact Indica Labs by phone (+81 (0)70 4180 7730) or email (hmakino@indicalab.com).

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

2017年1月9日

Indica Labs Inc.(本社・アメリカ、以下インディカ・ラボという)は今月から日本におけるカントリーマネージャーとして牧野英哉を採用し、東京に新たな拠点を設けることで、国際的なプレゼンスを継続的に拡大していきます。牧野はこれまでRoche、Leica、Aperio、Roper Technologiesといった前職で得られた計14年以上の経験をもとに、顕微鏡、デジタル病理学、画像解析の分野における実績を積み重ねてきました。
インディカ・ラボは2012年以来、着実にグローバルビジネスを展開しています。東京に加えて、これまで英国および米国に拠点を置き、既にヨーロッパおよび北米の顧客に向け専門的なサポートを提供しています。
インディカ・ラボのCEO、Steven Hashagenは次のように述べています。
「インディカ・ラボは、すべてのお客様に優れたサービスとサポートを提供することを約束しています。過去2年間、アジア、特に日本でのインディカ・ラボの製品の採用は劇的に増加しました。私たちの製品に特化し、タイムリーに、そして現地語で顧客に対応できる代表者の存在は、この成長する顧客基盤に最高品質のサポートを提供するために不可欠です。日本におけるIndica Labsを代表して牧野氏がこの取り組みを指揮してくれることを嬉しく思っています」
販売およびサポートに関するお問い合わせがある場合は、電話(070-4180-7730)または電子メール(hmakino@indicalab.com)でインディカ・ラボにご連絡ください。

<Indica Labs Inc.について>
Indica Labs Inc.は、デジタル病理画像の定量的評価のためのソフトウェアの大手プロバイダーです。 インディカ・ラボのHALO™画像解析プラットフォームは、業界をリードする幅広いアプリケーション特有の画像解析モジュールの基盤となる、精度、性能、スケーラビリティ、ユーザビリティの独自性の高い組み合わせを持つサービスをご提供いたします。世界中の医薬品および医療研究機関で、神経科学、代謝、腫瘍学、毒物学的病理学などの組織ベースの研究プログラムをサポートするためにHALOを利用しています。
詳細については、http://indicalab.com/ をご覧ください。

Indica Labs invites you to Cruise Chicago with us

Indica Labs, in conjunction with Global Engage Digital Pathology Congress 2017, formally invites you to take in a unique view of the Chicago Skyline while enjoying dinner and drinks with your conference delegates as you cruise the Chicago River on this 90 ft luxury yacht!

Event Date
Sunday, July 9th, 2017

Event Times
6:00 PM                    Guest Loading
6:30 PM Prompt      Yacht Departure for Sunset Cruise – Dinner & Drinks will be served
8:30 PM                    Yacht Returns to Harbor & Guest Depart Ship

Event Location
Anita Dee I Yacht at DuSable Harbor
200 N Breakwater Access
Chicago, IL 60601

Transportation
Starting at 5:30 PM – there will be a shuttle taking guests from the Palmer House Hilton Hotel to the Harbor, and returning guests to the hotel at the end of the cruise

Parking
For guests who choose to drive, there is parking available at the DuSable Harbor Parking Lot – rates range from $16-$24

RSVP by Wednesday July 5th
Email your Full Name, Company & Title to marketing@indicalab.com to RSVP for this Exclusive Dinner Event.

 

 

Indica Labs advance immuno-oncology capabilities with innovative quantification of multiplexed chromogenic immunohistochemistry

Corrales, NM – 2 November, 2016 – Indica Labs, a leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce the release of a new module for multiplex chromogenic IHC analysis using HALO™.  The Multiplex IHC module can separate up to five stains simultaneously and analyze any subcellular compartment, nucleus, cytoplasm or membrane, making it ideally suited for applications in immuno-oncology where multiple markers are required to characterize distinct immune and tumor cell populations within the tissue.

Due to limitations with traditional color deconvolution, digital pathology image analysis has been largely limited to single or dual immunohistochemistry and analysis of more than two stains could only be accomplished using serial section alignment or immunofluorescence and fluorescence slide scanning.   The Multiplex IHC overcomes these barriers using advanced color unmixing and cell segmentation protocols to facilitate multiplex analysis from a single slide without the need for expensive, time-consuming fluorescent image capture or serial section analysis.  Using fast brightfield whole-slide image acquisition and analysis, Multiplex IHC paves the way for more rapid, cost effective multiplex biomarker evaluation.  An example of 4-plex IHC analysis is shown in figure below.


4-way color decnvolution

Figure 1. 4-plex IHC stained tissue (A). With advanced color deconvolution using HALOs Multiplex IHC module, we can visualize (B) hematoxylin counterstain (C) brown nuclear marker, (D) blue membrane marker, and (E) pink/red cytoplasmic marker. The positivity of each marker is measured in each subcellular compartment based on user-determined thresholds and the resulting mark-up image is shown in (F). Advanced staining courtesy of the Trev and Joyce Deeley Research Centre, BC Cancer Agency


Indica Labs, CEO, Steven Hashagen commented, “HALO product development has always been driven by customer needs and the Multiplex IHC module is no exception.  Chromogenic multiplexing has become increasingly more important in immuno-oncology, and our revolutionary color deconvolution technology opens many doors in this area.”

To request a live demonstration, software trial or upgrade to your existing HALO platform, please contact us at info@indicalab.com.

About Indica Labs, Inc. 

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

 

 

November 15th Webinar: Introducing HALO Link, Collaborative Pathology Information System

Indica Labs invites you to attend our November webinar:

Introducing HALO Link, Collaborative Pathology Information System

Tuesday November 15th | 8 AM PST | 11 AM EST | 4 PM GMT
Presented by Kate Tunstall Ph.D, CSO

Designed with image analysis users in mind, Indica Labs introduces HALO LinkTM, a collaborative digital pathology information system which integrates seamlessly with the HALOTM image analysis platform.  In this 45-minute webinar, we will demonstrate how HALO Link can be used to:
Organize whole slide images into studies and grant collaborators remote access to studies using role-based sharing
Automate data entry with barcodes and integration to external databases
View, annotate and run analysis on whole slide images outside of HALO using an advanced browser-based viewer
Perform quality control on your analysis results and view trends across slides using integrated plots

 

Register Now

You’re Invited to our European Quantitative Pathology Meeting

You’re Invited

 Indica Labs would like to formally invite you to our European Quantitative Pathology Meeting in London which will be held on Wednesday 30th November from 12:00-5 PM at the London Marriott Heathrow Hotel.

Customer presenters representing diverse organizations,including pharma, biotech, and academic medical centres across Europe will discuss how they are using HALO image analysis to achieve their research objectives with an emphasis on biomarker analysis in oncology, particularly immuno-oncology. Additionally, there will be presentations from Indica Labs introducing new features in HALO and STRATA and a demonstration of our new data management platform, HALO Link.

You do not need to be a current HALO user or Indica Labs customer to attend.  We welcome anyone who is interested in learning more about HALO quantitative pathology from their peers to register for the meeting.

Presenters

Speaker Grid (2)

Users can register by emailing Liz Amdahl, liz@indicalab.com

This meeting is being held in conjunction with the Digital Pathology Congress at the same venue; however, attendance at the user group does not require registration for the congress.

 

 

Webinar September 28th | Evaluating Immune Checkpoint Biomarkers in Melanoma using HALO and STRATA

Case Study using HALO™ and STRATA™:
Biomarkers of Anti-tumor Immune Activity Associate with Survival in Melanoma

Wednesday Septmber 28th | 8 AM PDT | 11 AM EDT | 4 PM BST
Presenters
Dr. Tricia Cottrell, Johns Hopkins Medical School 
Vlado Ovtcharov, Indica Labs

PD-L1 expression in the tumor microenvironment can be both prognostic and predictive.  PD-L1 expression is often a marker of an ongoing CD8+ cytotoxic T-cell-mediated anti-tumor immune response, and thus, patients with PD-L1-positive melanomas have improved overall survival relative to those with PD-L1- negative melanomas. PD-L1 expression and high CD8-T-cell density have also been associated with an increased probability of response to PD-1 pathway blockade therapies in melanoma.

In this webinar, Dr. Cottrell and Mr Ovtcharov will describe recent studies using digital image analysis with Indica Labs’ HALOTM and STRATATM platforms to characterize immunohistochemical features of the tumor microenvironment and correlate them with survival for patients with melanoma.

Register Here 


Dr. Cottrell’s Bio

Dr. Tricia Cottrell from Johns Hopkins School of Medicine is a post-doctoral fellow in the lab of Dr. Janis Taube.  Dr. Taube’s laboratory described PD-L1-mediated adaptive immune resistance by melanoma, a finding that has now been extended to other tumor types. She also developed a robust immunohistochemistry assay and interpretation methods for studying PD-L1 as it relates to therapeutic response.  Versions of this assay are now approved by the U.S. Food and Drug Administration for clinical use.  Dr. Cottrell’s work in the Taube lab focuses on the use of digital image analysis platforms for quantitative characterization of biomarkers in the tumor microenvironment for improve prognostic and predictive applications.

 

 

 

Join Indica Labs at the 2nd Digital Pathology Congress in Philadelphia

Indica Labs’ Sales Application Scientist Adam Smith will be presenting on the STRATA Platform July 14th from 11:45-12:15 at the 2nd Digital Pathology Congress in Philadelphia. His presentation will focus on the connection of Image Analysis resulting in the collection of millions of data points and data point combinations. STRATA provides a connection between this image analysis data and patient data in order to determine how these two data silos are correlated. From these correlations we can use STRATA to QC data, identify/optimize cut points, and create predictive classifiers of patient response. Please stop by our booth #5 for a further demonstration of STRATA, and as well as, HALO 2.0.

ACD and Indica Labs Present a Joint Webinar Event

Current State-of-the-Art Tissue-Based RNA Analysis with RNAscope Technology and Quantitative Analysis with the HALO Image Analysis Platform 

June 1st, 2016, 8 am PDT | 11 am EDT | 4 pm BST (GMT+1)

Advanced Cell Diagnostics’ RNAscope® platform is fast becoming a routinely used method for target validation and biomarker development based on in situ gene expression analysis. ACD has nearly 9000 target RNA-specific probes in use and there are over 400 publications with the method. RNAscope® technology enables faster and more rigorous target and biomarker development: it is a robust and ultra-sensitive RNA in situ hybridization (RNA ISH) method providing single-cell and single-molecule RNA detection in the context of complex tissue microenvironments. In this webinar the RNAscope® technology and published applications will be presented by ACDBio.  Quantitative analysis of single/dual chromogenic probes and multiplex fluorescent probes using the HALO platform will be demonstrated by Indica Labs.

Presenters:
Courtney Anderson, PhD- Senior Scientist, R&D, ACDBio
Sean Griffiths, PhD- Application Scientist, Indica Labs 

Webinar: Introducing Strata

Introducing STRATATM| Mining tissue-based analysis data to identify predictive and/or prognostic factors using STRATA, an integrated tissue informatics platform 

May 3rd, 2016, 8 am PDT | 11 am EDT | 4 pm BST (GMT+1)

 

Combining multiplexed, spatially-resolved analysis capabilities with the fastest processing speeds in the industry, Indica Labs’ HALO™ analysis platform allows scientists to quickly generate vast amounts of biomarker expression data from large patient populations.  As the volume of analysis data increases, the challenge shifts from data collection to data mining. In this 30-minute webinar, Indica Labs introduces STRATA™, a new platform for visualizing, managing and mining biomarker analysis data to identify end points associated with patient outcomes.

Hosted by Dr. Kate Lillard Tunstall, PhD, CSO Indica Labs

REGISTER HERE  

More info about STRATA

Indica Labs announce release of HALO 2.0

Corrales, NM – 11 April, 2016 – Indica Labs, a leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce the latest release of its flagship image analysis platform, HALOTM.  Established as the industry’s fastest and most user-friendly analysis platform, HALO 2.0 adds new capabilities, support for new file formats, and even greater ease-of-use.

Those familiar with HALO will recognize the new, more modern look-and-feel of HALO 2.0 including interchangeable dark and light skins designed to ease eye-strain when working with darkfield and brightfield images.  While this is the most obvious change, improvements are much more than skin deep.  HALO 2.0 adds a new tuning interface to make analysis set-up even easier, the ability to create spatial plots, heat maps, and histograms from any HALO analysis result, and tools for data import/export, sharing, archiving, and report generation.

New modules are also available with HALO 2.0, including spatial analysis and high-plex FL.  Particular important for those conducting immuno-oncology and angiogenesis research, the spatial analysis module is actually a suite of tools for analysing proximity and relative spatial distribution of objects, cells and/or features across single tissues or serial sections.  The high-plex FL module allows for simultaneous analysis of up to 8 markers and can be used in conjunction with most fluorescent whole-slide image format, including newly added support for multispectral floating-point qptiff images and whole-slide images produced from the Perkin-Elmer Vectra® 3 platform.

“Driven by our commitment to customer-centric product development, HALO has evolved rapidly and, in a relatively short space of four years, has become the image analysis platform of choice by 10 out of the top 12 pharmaceutical companies and hundreds of pathology labs worldwide,” says Steven Hashagen, CEO of Indica Labs, “With HALO 2.0, we are again improving ease-of-use while at the same time incorporating new features requested by the HALO community.”

Please follow this link  to view our recent webinar covering some of the new features in HALO 2.0.  To request a live demonstration, software trial or upgrade to your existing HALO platform, please contact us at info@indicalab.com.

 

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

Inaugural East Coast HALO User Group to be held in Cambridge, MA on February 11, 2016

 

Indica Labs would like to formally invite you to the Inaugural East Coast HALOTM User Group Meeting which will be held on 11th February, 2016 from 1- 5 PM at the Boston Marriott Cambridge, Kendall Square. Lunch (12-1 PM) and happy hour refreshments (5-6 PM) will be available to all registered attendees. Both current HALO users and those interested in learning about HALO and other Indica Labs software are welcome to attend and participate.

Indica Labs CSO, Dr. Kate Lillard, and East Coast Application Scientist, Adam Smith, will demonstrate some of the new features in HALO and introduce a completely new software platform. Additionally, we are pleased to have the following local HALO users presenting at the meeting:

 

alnylamcircle1Dr. Kristina Perry

Scientist
Drug Safety and Metabolism
Alnylam Pharmaceuticals

 

 

jimround1Jim Deeds

Senior Technical Leader
Oncology Targets & Biomarkers
Novartis | NIBR

 

chandracircle1Dr. Chandra Saravanan

Molecular Pathologist
Novartis | NIBR

 

 

alexround1Dr. Alexander Klimowicz

Principal Scientist, Immunology and Inflammation Research
Boehringer Ingelheim

 

 

To register your interest in attending this event, please email your contact details to Elizabeth Amdahl, liz@indicalab.com.

We look forward to seeing you at the meeting!

Boehringer Ingelheim Principal Scientist Alex Klimowicz and Indica Labs CSO Kate Lillard to present at Pathology Visions Boston

 

Discoveries from the field:  Expediting drug developments and clinical trials with digital pathology and HALO image analysis

Alex Klimowicz, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals

Kate Lillard Tunstall, PhD, CSO, Indica Labs

 

In this 60-minute presentation, our speakers will detail how the HALO image analysis platform has been used to analyze biomarkers in translational research and drug development, respectively. So please join us October Tuesday 13th at 8 a.m. in the Carlton Ballroom at the Westin Waterfront Hotel, at the Pathology Visions Conference.

Supported File Formats:


  • – Non Proprietary (JPG, TIF)
  • – 3D Histech (MRXS)
  • – Aperio (SVS, AFI, eSlideManager)
  • – Hamamatsu (NDPI, NDPIS)
  • – Leica (SVS, SCN, LIF)
  • – Mikroscan (TIF)
  • – Nikon (ND2)
  • – Olympus (VSI)
  • – Perkin Elmer (QPTIFF, Vectra TIF)
  • – Philips IMS
  • – Zeiss (CZI)

Don’t see the format you’re looking for? Contact us to make a request

CLOSE
Thank you for signing-up. Please check your email for link to access webinar recording.